Abstract
Following the introduction of black tar heroin mainly from Mexico in the 1980s, cases of wound botulism dramatically increased in the western United States. Contamination with spores of Clostridium botulinum of black tar heroin occurs along the distribution line. The heating of heroin powder to solubilize it for subcutaneous injection (“skin popping”) does not kill the spores. The spores germinate in an anaerobic tissue environment and release botulinum toxin type A or B. Unless skin abscesses are found in the patient, the clinical diagnosis is often challenging. Facilitation of the compound muscle action potential by repetitive nerve stimulation at 20 to 50 Hz is an important and rapid diagnostic test. Definite diagnosis is made by detection of botulinum toxin in serum or isolation of C botulinum from the abscess. Early treatment with equine ABE botulinum antitoxin obtained from the Centers for Disease Control and Prevention often shortens the time on a ventilator.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Centers for Disease Control and Prevention: Botulism in the United States, 1899–1996. Handbook for Epidemiologists, Clinicians, and Laboratory Workers. Atlanta, GA: Centers for Disease Control and Prevention; 1998.
Weber JT, Goodpasture HC, Alexander H, et al.: Wound botulism in a patient with a tooth abscess: case report and review. Clin Infect Dis 1993, 16:635–639.
Merson MH, Dowell VR: Epidemiologic, clinical and laboratory aspects of wound botulism. N Engl J Med 1973, 289:1005–1010.
Werner SB, Passaro D, McGee J, et al.: Wound botulism in California, 1951-1998: recent epidemic in heroin injectors. Clin Infect Dis 2000, 31:1018–1024.
MacDonald KL, Rutherford GW, Friedman S, et al.: Botulism and botulism-like illnesses in chronic drug users. Ann Intern Med 1985, 102:616–618.
Passario DJ, Werner SB, McGee J, et al.: Wound botulism associated with black tar heroin among injecting drug users. JAMA 1998, 279:859–863.
Centers for Disease Control and Prevention: Summary of notifiable diseases—United States, 2005. MMWR Morb Mortal Wkly Rep 2007, 54:2–92.
Brett MM, Hallas G, Mpamugo O: Wound botulism in the UK and Ireland. J Med Microbiol 2004, 53:555–561.
sGalldiks N, Nolden-Hoverath S, Kosinski CM, et al.: Rapid geographical clustering of wound botulism in Germany after subcutaneous and intramuscular injection of heroin. Neurocrit Care 2007, 6:630–634.
Kudrow DB, Henry DA, Haake DA, et al.: Botulism associated with Clostridium botulinum sinusitis after intranasal cocaine abuse. Ann Intern Med 1988, 109:984–985.
Sobel J: Botulism. Clin Infect Dis 2005, 41:1167–1173.
Bleck TP: Clostridium botulinum (botulism). In Principles and Practice of Infectious Diseases, edn 5. Edited by Mandell GL, Bennett JE, Dolin R. Philadelphia: Churchill Livingstone; 2000:2543–2548.
Microbiological investigation into wound botulism. Commun Dis Rep CDR Wkly 2000, 10:185, 188.
Simpson LL: Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 2004, 44:167–193.
Hatheway CL, Ferreira JL: Detection and identification of Clostridium botulinum neurotoxins. Adv Exp Med Biol 1996, 391:481–498.
Sugiyama H: Clostridium botulinum neurotoxin. Microbiol Rev 1980, 44:419–448.
Horowitz BZ: Botulinum toxin. Crit Care Clin 2005, 21:825–839.
Pestronk A, Drachman DB: Motor nerve outgrowth: reduced capacity for sprouting in the terminals of longer axons. Brain Res 1988, 463:218–222.
US Drug Enforcement Administration: Heroin: description/overview. Available at http://www.usdoj.gov/dea/concern/heroin.html. Accessed September 25, 2008.
National Institute on Drug Abuse: Heroin Abuse and Addiction. Available at http://www.drugabuse.gov/ResearchReports/Heroin/Heroin.html. Accessed September 25, 2008.
Maselli RA, Ellis W, Mandler RN, et al.: Cluster of wound botulism in California: clinical, electrophysiologic, and pathologic study. Muscle Nerve 1997, 20:1284–1295.
US Public Health Service: National Household Survey on Drug Abuse: Population Estimates 1994. Rockville, MD: US Department of Health and Human Services; 1995. [DHHS publication SMA 95-3093.]
Penas SC, Faria OM, Serrao R, et al.: Ophthalmic manifestations in 18 patients with botulism diagnosed in Porto, Portugal between 1998 and 2003. J Neuroophthalmol 2005, 25:262–267.
Cooper JG, Spilke CE, Benton M, Jamieson S: Clostridium botulinum: an increasing complication of heroin misuse. Eur J Emerg Med 2005, 12:251–252.
Mitchell PA, Pons PT: Wound botulism associated with black tar heroin and lower extremity cellulitis. J Emerg Med 2001, 20:371–375.
Centers for Disease Control and Prevention: Wound botulism—California, 1995. MMWR Morb Mortal Wkly Rep 2005, 44:889–892.
American Association of Neuromuscular and Electrodiagnostic Medicine: Practice Parameter for Repetitive Nerve Stimulation and Single Fiber EMG Evaluation of Adults With Suspected Myasthenia Gravis or Lambert-Eaton Myasthenic Syndrome: Summary Statement. Available at http://www.aanem.org/education/practiceguidelines/mg.cfm. Accessed September 25, 2008.
De Jesus PV Jr, Slater R, Spitz LK, Penn AS: Neuromuscular physiology of wound botulism. Arch Neurol 1973, 29:415–431.
Shapiro BE, Soto O, Shafqat S, Bluenfeld H: Adult botulism. Muscle Nerve 1997, 20:100–102.
Ryan DW, Cherington M: Human type A botulism. JAMA 1971, 216:513–514.
Edel TA, Sullivan CP, Osborn KM, et al.: Wound botulism associated with a positive Tensilon test. West J Med 1983, 139:218–219.
Lo YL: Clinical and immunological spectrum of the Miller Fisher syndrome. Muscle Nerve 2007, 36:615–627.
Robinson RF, Nahata MC: Management of botulism. Ann Pharmacother 2003, 37:127–131.
Lindstrom M, Korkeala H: Laboratory diagnosis of botulism. Clin Microbiol Rev 2006, 19:298–314.
Mulleague L, Bonner SM, Samuel A, et al.: Wound botulism in drug addicts in the United Kingdom. Anesthesia 2001, 56:120–123.
Davis LE: Botulism. Curr Treat Option Neurol 2003, 5:23–31.
Sandrock DF, Murin S: Clinical predictors of respiratory failure and long-term outcome in black tar heroin-associated wound botulism. Chest 2001, 120:562–566.
Kramer AH, Bleck TP: Neurocritical care of patients with central nervous system infections. Curr Infect Dis Rep 2007, 9:308–314.
Tacket CO, Shandera WX, Mann JM, et al.: Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med 1984, 76:794–798.
Hatheway CL, Snyder JD, Seals JE, et al.: Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. J Infect Dis 1984, 150:407–412.
Arnon SS, Schechter R, Inglesby TV, et al.: Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001, 285:1059–1070.
Black RE, Gunn RA: Hypersensitivity reactions associated with botulinal antitoxin. Am J Med 1980, 69:567–570.
Santos JI, Swensen P, Glasgow LA: Potentiation of Clostridium botulinum toxin by aminoglycoside antibiotics: clinical and laboratory observations. Pediatrics 1981, 68:50–54.
Mechem CC, Walter FG: Wound botulism. Vet Hum Toxicol 1994, 36:233–237.
Woodruff BA, Griffin PM, McCroskey LM, et al.: Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States, 1975–1988. J Infect Dis 1992, 166:1281–1286.
Mann JM, Martin S, Hoffman R, Marrazzo S: Patient recovery from type A botulism: morbidity assessment following a large outbreak. Am J Public Health 1981, 71:266–269.
Keller JE: Recovery from botulinum neurotoxin poisoning in vivo. Neuroscience 2006, 139:629–637.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Davis, L.E., King, M.K. Wound botulism from heroin skin popping. Curr Neurol Neurosci Rep 8, 462–468 (2008). https://doi.org/10.1007/s11910-008-0074-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11910-008-0074-2